Cetirizine Hydrochloride Solution
Product Images NDC 16571-134

10 FDA label images from Rising Pharma Holdings, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Cetirizine Hydrochloride (NDC 16571-134). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rising Pharma Holdings, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical-structure (Cetirizine Structure)

Chemical-structure (Cetirizine Structure)
Chemical structure of cetirizine hydrochloride, a compound shown with chlorophenyl groups, piperazine ring, and carboxyl group consistent with the generic name provided.*
FDA Label Image

Cetirizine-label-1 (Cetirizine Label 1)

Cetirizine-label-1 (Cetirizine Label 1)
Label for CETIRIZINE HYDROCHLORIDE oral solution, USP, 5 mg/5 mL (1 mg/mL) grape flavored, 4 fl. oz. (120 mL) bottle, distributed by Rising Pharma Holdings, Inc. The label includes storage instructions and states it is for oral use only with a notice for prescription use.*
FDA Label Image

Cetirizine-label-2 (Cetirizine Label 2)

Cetirizine-label-2 (Cetirizine Label 2)
This is a drug information panel for Cetirizine Hydrochloride oral solution 1 mg/mL. It includes a chemical structure diagram, description of the drug as a white crystalline powder in a colorless to slightly yellow oral solution, inactive ingredients, and clinical pharmacology details covering mechanism of action, pharmacokinetics (absorption, distribution, metabolism), and study observations on efficacy and safety.*
FDA Label Image

Cetirizine-label-3 (Cetirizine Label 3)

Cetirizine-label-3 (Cetirizine Label 3)
Text panels outlining pharmacokinetics, interaction studies, effects in special populations including pediatric patients, and pharmacodynamics of cetirizine hydrochloride oral solution. Details cover elimination, interaction with other drugs, effects of race and gender, and clinical study results on histamine-induced responses and QTc intervals.*
FDA Label Image

Cetirizine-label-4 (Cetirizine Label 4)

Cetirizine-label-4 (Cetirizine Label 4)
Drug facts and prescribing information for Cetirizine Hydrochloride oral solution describe clinical studies, indications, contraindications, and precautions. The panel details efficacy in perennial allergic rhinitis and chronic urticaria, safety in pediatric patients, and warnings about mental alertness and somnolence during use.*
FDA Label Image

Cetirizine-label-5 (Cetirizine Label 5)

Cetirizine-label-5 (Cetirizine Label 5)
This text panel discusses risks of new onset pruritus after discontinuation of cetirizine, potential drug-drug interactions, and carcinogenesis, mutagenesis, and impairment of fertility studies. It summarizes findings from animal studies and highlights the lack of significant mutagenic or carcinogenic effects at tested doses.*
FDA Label Image

Cetirizine-label-6 (Cetirizine Label 6)

Cetirizine-label-6 (Cetirizine Label 6)
Text panel titled 'Pediatric Use' and 'Adverse Reactions' for cetirizine hydrochloride oral solution 1 mg/mL. It discusses safety and effectiveness in pediatric patients aged 6 months to 11 years, clinical trial data, dosing, and a summary of adverse reactions, including frequency of side effects in pediatric clinical trials.*
FDA Label Image

Cetirizine-label-7 (Cetirizine Label 7)

Cetirizine-label-7 (Cetirizine Label 7)
A data table summarizing adverse experiences reported at rates of 5 mg or 10 mg Cetirizine Hydrochloride compared to placebo in clinical trials. The table lists events such as headache, pharyngitis, abdominal pain, and others with corresponding percentage incidence for placebo and two Cetirizine dosing groups. Additional text lists infrequent adverse events and categorizes adverse experiences by body system including cardiovascular, neurological, gastrointestinal, and others.*
FDA Label Image

Cetirizine-label-8 (Cetirizine Label 8)

Cetirizine-label-8 (Cetirizine Label 8)
This image displays the dosage and administration instructions, overdosage warnings, and post-marketing experience information for Cetirizine Hydrochloride oral solution 1 mg/mL by Rising Pharma Holdings, Inc. It includes dosing guidelines for children aged 6 months to 5 years, storage conditions, and distributor information.*
FDA Label Image

Cetirizine-label-9 (Cetirizine Label 9)

Cetirizine-label-9 (Cetirizine Label 9)
Label for Cetirizine Hydrochloride Oral Solution, USP 1 mg/mL (5 mg/5 mL) by Rising Pharma Holdings, Inc. The grape-flavored oral solution is packaged in a 4 fl. oz. (120 mL) container. The label includes storage instructions, dosage note, and a barcode with product NDC 16571-134-12.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.